ANP to present at and attend major US investment, partnering and industry conferences
TOORAK, Australia, Aug. 28, 2013 /PRNewswire/ — Antisense Therapeutics Limited (ASX:ANP) is pleased to advise that its Chief Executive Officer and Managing Director, Mark Diamond has been invited to present at two major investment and partnering focused conferences in the US, and will also attend an industry seminar on orphan drugs and rare diseases as the Company steps up its planning on its drug ATL1103 for acromegaly.
The investment and partnering focused conferences will involve a presentation on ANP and its projects, which will be followed by a series of one on one meetings with investors and companies attending the pharmaceutical partnering conference.
Conference and seminar details as follows:
1. Rodman & Renshaw Annual Global Investment Conference, September 8-10, 2013, New York, US
The Company’s presentation is scheduled to begin at 8.45am Eastern US time on Tuesday 10 September which will be available via a live webcast. To access the webcast, please go to http://wsw.com/webcast/rrshq23/ANP.AX
A replay of the webcast will be available for 90 days and may be accessed by visiting the ANP website www.antisense.com.au
2. Biopharma America Partnering Conference, September 17-19, 2013, Boston, US
The Company’s presentation is scheduled to begin at 2.15pm Eastern US time on Wednesday 18 September, 2013.
3. Orphan Drugs & Rare Disease Seminar, September 12, 2013, Princeton, US
For further information please contact:
USA Investor/Media: Joshua Drumm 212-375-2664; email@example.com
Australia Investor/Media: Simon Watkin +61 413 153272; firstname.lastname@example.org
Antisense Therapeutics Limited (ASX: ANP) is an Australian publicly listed biopharmaceutical drug discovery and development company. Its mission is to create, develop and commercialise second generation antisense pharmaceuticals for large unmet markets. ANP has 4 products in its development pipeline that it has in-licensed from Isis Pharmaceuticals Inc., world leaders in antisense drug development and commercialisation – ATL1102 (injection) which has successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with multiple sclerosis, ATL1103 a second-generation antisense drug designed to block GHr production and thereby lower blood IGF-I levels and is in clinical development as a potential treatment for growth and other GH-IGF-I disorders, ATL1102 (inhaled) which is at the pre-clinical research stage as a potential treatment for asthma and ATL1101 a second-generation antisense drug at the pre-clinical stage being investigated as a potential treatment for cancer.
SOURCE Antisense Therapeutics Limited